A Randomised Controlled Trial Comparing the Efficacy of Infant Peri-exposure Prophylaxis With Lopinavir/Ritonavir (LPV/r) Versus Lamivudine to Prevent HIV-1 Transmission by Breastfeeding.

Trial Profile

A Randomised Controlled Trial Comparing the Efficacy of Infant Peri-exposure Prophylaxis With Lopinavir/Ritonavir (LPV/r) Versus Lamivudine to Prevent HIV-1 Transmission by Breastfeeding.

Completed
Phase of Trial: Phase III

Latest Information Update: 07 Mar 2018

At a glance

  • Drugs Lopinavir/ritonavir (Primary) ; Lamivudine
  • Indications HIV-1 infections
  • Focus Therapeutic Use
  • Acronyms PROMISE-PEP
  • Most Recent Events

    • 07 Mar 2018 Results (n=151) assessing the mitochondrial toxicity of 3TC or LPV/r regimens after 1 year of PrEP among HIV-exposed uninfected infants, were presented at the 25th Conference on Retroviruses and Opportunistic Infections.
    • 06 Mar 2014 Status changed from active, no longer recruiting to completed.
    • 06 Mar 2014 Results presented at the 21st Conference on Retroviruses and Opportunistic Infections.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top